|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||
| CURRENT ASSETS: | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Accounts receivable, net of allowance for credit losses of $6,504 and $6,317 at 2026 and 2025, respectively | |||||||||||||
| Inventories | |||||||||||||
| Prepaid expenses | |||||||||||||
| Income taxes receivable | |||||||||||||
| Other current assets | |||||||||||||
| TOTAL CURRENT ASSETS | |||||||||||||
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $318,900 and $320,707 at 2026 and 2025, respectively | |||||||||||||
| RIGHT OF USE ASSETS | |||||||||||||
| INTANGIBLES, net of accumulated amortization and impairment of $19,879 and $19,531 at 2026 and 2025, respectively | |||||||||||||
| GOODWILL | |||||||||||||
| DEFERRED TAX ASSETS, net | |||||||||||||
| OTHER ASSETS | |||||||||||||
| TOTAL ASSETS | |||||||||||||
| LIABILITIES AND EQUITY | |||||||||||||
| CURRENT LIABILITIES: | |||||||||||||
| Accounts payable | |||||||||||||
| Accrued payroll and related costs | |||||||||||||
| Taxes other than payroll and income | |||||||||||||
| Unearned revenues | |||||||||||||
| Operating lease liabilities | |||||||||||||
| Income taxes payable | |||||||||||||
| Other current liabilities | |||||||||||||
| TOTAL CURRENT LIABILITIES | |||||||||||||
| LONG-TERM DEBT, net | |||||||||||||
| LONG-TERM OPERATING LEASE LIABILITIES | |||||||||||||
| DEFERRED COMPENSATION | |||||||||||||
| DEFERRED TAX LIABILITIES, net | |||||||||||||
| OTHER LONG-TERM LIABILITIES | |||||||||||||
| EQUITY: | |||||||||||||
| Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding | |||||||||||||
| Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 45,884,100 outstanding at 2026; 46,966,868 issued and 46,095,379 outstanding at 2025 | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Retained earnings | |||||||||||||
| Accumulated other comprehensive income (loss) | |||||||||||||
| Treasury stock (at cost), 1,082,768 and 871,489 shares at 2026 and 2025, respectively | |||||||||||||
| Total Core Laboratories Inc. shareholders' equity | |||||||||||||
| Non-controlling interest | |||||||||||||
| TOTAL EQUITY | |||||||||||||
| TOTAL LIABILITIES AND EQUITY |
Loading...
